One-year data from the REMAIN-1 study show Revita enables patients to maintain up to 84% of GLP-1-induced weight loss after stopping medication, with a strong safety profile and minimal adverse events. Durable, drug-free weight maintenance was achieved with a single outpatient procedure, supporting broad clinical adoption.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.